Marshall & Sullivan Inc. WA Has $4.74 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Marshall & Sullivan Inc. WA trimmed its position in shares of Danaher Co. (NYSE:DHR) by 0.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,134 shares of the conglomerate’s stock after selling 92 shares during the quarter. Danaher makes up 2.4% of Marshall & Sullivan Inc. WA’s holdings, making the stock its 20th biggest holding. Marshall & Sullivan Inc. WA’s holdings in Danaher were worth $4,742,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Kentucky Retirement Systems Insurance Trust Fund raised its position in shares of Danaher by 11.6% during the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate’s stock worth $4,874,000 after acquiring an additional 2,202 shares during the last quarter. FAS Wealth Partners Inc. lifted its stake in shares of Danaher by 20.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate’s stock worth $2,203,000 after acquiring an additional 1,639 shares during the period. Generate Investment Management Ltd acquired a new position in shares of Danaher in the fourth quarter worth approximately $8,044,000. Compass Capital Management Inc. lifted its stake in shares of Danaher by 4.8% in the fourth quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate’s stock worth $54,615,000 after acquiring an additional 10,994 shares during the period. Finally, Channing Global Advisors LLC lifted its stake in shares of Danaher by 42.8% in the fourth quarter. Channing Global Advisors LLC now owns 5,666 shares of the conglomerate’s stock worth $1,301,000 after acquiring an additional 1,698 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Down 0.5%

Shares of NYSE:DHR opened at $189.04 on Tuesday. The stock has a market cap of $135.29 billion, a price-to-earnings ratio of 35.80, a PEG ratio of 2.66 and a beta of 0.80. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12-month low of $171.00 and a 12-month high of $281.70. The business’s 50 day moving average is $192.30 and its 200 day moving average is $213.12.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. On average, sell-side analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.68%. Danaher’s dividend payout ratio is currently 24.85%.

Insiders Place Their Bets

In other news, EVP Christopher Paul Riley sold 15,805 shares of the company’s stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the transaction, the executive vice president now owns 15,179 shares of the company’s stock, valued at $3,005,442. This represents a 51.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the company’s stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the transaction, the chairman now directly owns 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on DHR shares. Jefferies Financial Group cut their price objective on Danaher from $260.00 to $230.00 and set a “buy” rating on the stock in a research note on Tuesday, April 22nd. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a research note on Sunday. UBS Group cut their price objective on Danaher from $275.00 to $240.00 and set a “buy” rating on the stock in a research note on Wednesday, April 23rd. Robert W. Baird lowered their target price on Danaher from $231.00 to $225.00 and set an “outperform” rating for the company in a report on Wednesday, April 23rd. Finally, JPMorgan Chase & Co. lowered their target price on Danaher from $280.00 to $260.00 and set an “overweight” rating for the company in a report on Tuesday, April 22nd. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $263.24.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.